Allogene Therapeutics (ALLO) Earnings Date, Estimates & Call Transcripts $2.41 -0.10 (-3.98%) (As of 09/6/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateNov. 7EstimatedActual EPS (Aug. 7) -$0.32 Beat By $0.03 Consensus EPS (Aug. 7) -$0.35 Get Allogene Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for ALLO and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueALLO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALLO Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << Allogene Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($0.58)($0.44)($0.51)Q2 20244($0.58)($0.35)($0.43)Q3 20244($0.59)($0.30)($0.40)Q4 20244($0.59)($0.32)($0.41)FY 202416($2.34)($1.41)($1.74)Q1 20253($0.38)($0.33)($0.35)Q2 20253($0.38)($0.34)($0.36)Q3 20253($0.40)($0.35)($0.37)Q4 20253($0.44)($0.36)($0.39)FY 202512($1.60)($1.38)($1.46)Q1 20261($0.45)($0.45)($0.45)Q2 20261($0.45)($0.45)($0.45)ALLO Earnings Date and InformationAllogene Therapeutics last posted its earnings results on August 7th, 2024. The reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics has generated ($1.79) earnings per share over the last year (($1.79) diluted earnings per share). Earnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.38) to ($1.47) per share. Allogene Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off prior year's report dates.Read More Allogene Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/7/2024(Estimated)------- 8/7/2024Q2 2024($0.35)($0.32)+$0.03($0.29)--5/13/2024Q1 2024($0.41)($0.38)+$0.03($0.38)$0.01 million$0.02 million 3/14/2024Q4 2023($0.47)($0.43)+$0.04($0.35)$0.05 million$0.02 million11/2/2023Q3 2023($0.53)($0.37)+$0.16($0.37)$0.05 million$0.04 million 8/2/2023Q2 2023($0.59)($0.53)+$0.06($0.53)$0.01 million$0.04 million 5/3/2023Q1 2023($0.63)($0.68)($0.05)($0.68)$0.08 million$0.05 million Get the Latest News and Ratings for ALLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/2023Q4 2022($0.71)($0.66)+$0.05($0.66)$0.06 million$0.05 million 11/2/2022Q3 2022($0.62)($0.58)+$0.04($0.58)$0.01 million$0.05 million 8/9/2022Q2 2022($0.61)($0.52)+$0.09($0.52)$0.08 million$0.09 million 5/4/2022Q1 2022($0.59)($0.56)+$0.03($0.56)$0.10 million$0.06 million 2/23/2022Q4 2021($0.61)($0.54)+$0.07($0.54)-$0.05 million 11/4/2021Q3 2021($0.56)($0.57)($0.01)($0.57)-$0.05 million 8/3/2021Q2 2021($0.55)($0.53)+$0.02($0.53)$0.95 million$0.04 million 5/4/2021Q1 2021($0.46)($0.25)+$0.21($0.25)$24.50 million$38.35 million 2/24/2021Q4 2020($0.56)($0.53)+$0.03($0.53)-- 11/9/2020Q3 2020($0.54)($0.52)+$0.02($0.52)-- 8/5/2020Q2 2020($0.54)($0.53)+$0.01($0.53)-- 5/6/2020Q1 2020($0.58)($0.58)-($0.50)-- 2/27/2020Q4 2019($0.68)($0.58)+$0.10($0.58)-- 11/5/2019Q3($0.54)($0.50)+$0.04($0.50)-- Allogene Therapeutics Earnings - Frequently Asked Questions When is Allogene Therapeutics's earnings date? Allogene Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates. Learn more on ALLO's earnings history. Did Allogene Therapeutics beat their earnings estimates last quarter? In the previous quarter, Allogene Therapeutics (NASDAQ:ALLO) reported ($0.32) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.35) by $0.03. Learn more on analysts' earnings estimate vs. ALLO's actual earnings. How much revenue does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded annual revenue of $65,000.00. How much profit does Allogene Therapeutics generate each year? Allogene Therapeutics (NASDAQ:ALLO) has a recorded net income of -$327.27 million. ALLO has generated -$1.79 earnings per share over the last four quarters. What is Allogene Therapeutics's EPS forecast for next year? Allogene Therapeutics's earnings are expected to decrease from ($1.38) per share to ($1.47) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Fate Therapeutics Earnings Results Relay Therapeutics Earnings Results Vir Biotechnology Earnings Results Beam Therapeutics Earnings Results Neumora Therapeutics Earnings Results Enliven Therapeutics Earnings Results Adaptive Biotechnologies Earnings Results Ocugen Earnings Results enGene Earnings Results Greenwich LifeSciences Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Is Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 EarningsNVIDIA: Analysts Bullish Ahead of Earnings - Is It a Buy Now? This page (NASDAQ:ALLO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.